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Abstract
Background:  A reliable and precise classification is essential for successful diagnosis and
treatment of cancer. Gene expression microarrays have provided the high-throughput platform to
discover genomic biomarkers for cancer diagnosis and prognosis. Rational use of the available
bioinformation can not only effectively remove or suppress noise in gene chips, but also avoid one-
sided results of separate experiment. However, only some studies have been aware of the
importance of prior information in cancer classification.
Methods: Together with the application of support vector machine as the discriminant approach,
we proposed one modified method that incorporated prior knowledge into cancer classification
based on gene expression data to improve accuracy. A public well-known dataset, Malignant pleural
mesothelioma and lung adenocarcinoma gene expression database, was used in this study. Prior
knowledge is viewed here as a means of directing the classifier using known lung adenocarcinoma
related genes. The procedures were performed by software R 2.80.
Results: The modified method performed better after incorporating prior knowledge. Accuracy
of the modified method improved from 98.86% to 100% in training set and from 98.51% to 99.06%
in test set. The standard deviations of the modified method decreased from 0.26% to 0 in training
set and from 3.04% to 2.10% in test set.
Conclusion: The method that incorporates prior knowledge into discriminant analysis could
effectively improve the capacity and reduce the impact of noise. This idea may have good future
not only in practice but also in methodology.
Background
A reliable and precise classification is essential for success-
ful diagnosis and treatment of cancer. Thus, improve-
ments in cancer classification have attracted more
attention [1,2]. Current cancer classification is mainly
based on clinicopathological features, gene expression
microarrays have provided the high-throughput platform
to discover genomic biomarkers for cancer diagnosis and
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prognosis [3-5]. Microarray experiments also led to a
more complete understanding of the molecular variations
among tumors and hence to a more accurate and inform-
ative classification [6-9]. However, this kind of knowledge
is often difficult to grasp, and turning raw microarray data
into biological understanding is by no means a simple
task. Even a simple, small-scale, microarray experiment
generates thousands to millions of data points.
Current methods to help classifying human malignancies
based on microarray data mostly rely on a variety of fea-
ture selection methods and classifiers for selecting inform-
ative genes [10-12]. The ordinary process of gene
expression data is as follows: first, a subset of genes with
known classification is randomly selected (training set),
then, the classifier is trained in the above training set until
it is mature, finally, the classifier is used to perform the
classification of unknown gene expression data. Com-
monly employed methods of feature gene selection
included Nearest Shrunken Centroids (also known as pre-
diction analysis for microarrays, PAM), shrunken centro-
ids regularized discriminant analysis (SCRDA) and
multiple testing procedure(MTP). The conventional
methods of classification included k nearest-neighbor
classifiers(KNN), linear discriminant analysis(LDA), sup-
port vector machine(SVM), back-propagation artificial
neural network(BP-ANN) and etc, while the choice of
which is a matter of dispute among methodologists [13-
15]. So, improvement of existing methods or develop-
ment of new methods is needed for the analysis of gene
expression microarray data. Many gene expression signa-
tures have been identified in recent years for accurate clas-
sification of tumor subtypes [16-19]. It has been indicated
that rational use of the available bioinformation can not
only effectively remove or suppress noise in gene chips,
but also avoid one-sided results of separate experiment.
However, a relatively few attempts have been aware of the
importance of prior information in cancer classification
[20-22].
Lung cancer is one of the leading causes of cancer death
worldwide [23-26], can be classified broadly into small
cell lung cancer (SCLC) and non-small cell lung cancer
(NSCLC), and adenocarcinoma is the most common form
of lung cancer. Because in China the cigarette smoking
rate continues to be at a high level [27], a peak in lung
cancer incidence is still expected [28]. Therefore, only
lung cancer gene expression microarray dataset was
selected in the present study.
In summary, together with the application of support vec-
tor machine as the discriminant approach and PAM as the
feature gene selection method, we propose one method
that incorporates prior knowledge into cancer classifica-
tion based on gene expression data. Our goal is to
improve classification accuracy based on the publicly
available lung cancer microarray dataset [29].
Methods
Microarray dataset
In the present study, we analyzed the well-known and
publicly available microarray dataset, malignant pleural
mesothelioma and lung adenocarcinoma gene expression
database http://www.chestsurg.org/publications/2002-
microarray.aspx[29]. This Affymetrix Human GeneAtlas
U95Av2 microarray dataset contains 12 533 genes' expres-
sion profiles of 31 malignant pleural mesothelioma
(MPM) and 150 lung adenocarcinomas (ADCA, pub-
lished in a previous study [30]), aims to test expression
ratio-based analysis to differentiating between MPM and
lung cancer. In this dataset, a training set consisted of 16
ADCA and 16 MPM samples.
Microarray data preprocessing
The absolute values of the raw data were used, then they
were normalized by natural logarithm transformation.
This preprocessing procedure was performed by using R
statistical software version 2.80 (R foundation for Statisti-
cal Computer, Vienna, Austria).
Gene selection via PAM
Prediction analysis for microarrays (PAM, also known as
Nearest Shrunken Centroids) is a clustering technique
used for classification, it uses gene expression data to cal-
culate the shrunken centroid for each class and then pre-
dicts which class an unknown sample would fall into
based on the nearest shrunken centroid. Through this
process, it can also identify the specific genes that most
determine the centroid. The details of PAM method can be
found in several published studies [31,32]. Here we
adopted ten independent repeats of 10-fold cross-valida-
tion (CV) to avoid overlapping test sets. First, the preproc-
essed dataset was split into 10 subsets of approximately
equal size by random sampling, secondly, each subset in
turn was used for testing and the remaining 9 subsets for
training. The above procedure was repeated 10 times. The
error estimates were averaged to yield an overall error esti-
mate. Note that the training set included 100 samples
(16290 cases) and the test set included 100 samples (1810
cases) after the above ten independent repeats of 10-fold
cross-validation.
Gene selection via prior biological knowledge
Published studies were collected in the database National
Library of Medicine on the web (http://
www.ncbi.nlm.nih.gov/sites/entrez, Pubmed) from Jan
1st, 2000 until March 31st, 2009 according to the retrieval
strategy of "human lung adenocaicinoma" and published
in the journal entitled "Cancer Research". Prior knowl-
edge was viewed here as a means of directing the classifierJournal of Experimental & Clinical Cancer Research 2009, 28:103 http://www.jeccr.com/content/28/1/103
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using known lung adenocarcinoma genes. For the pur-
poses of this study, prior knowledge was any information
about lung adenocarcinoma related genes that have been
confirmed in literature. Hence, due to the journal's scope
and the author's institution's accessibility, we restricted
our attention to the journal entitled "Cancer Research".
Cancer Research's publication scope covers all subfields of
cancer research. The full texts of the papers were down-
loaded and then lung adenocarcinoma-related genes were
retrieved from the literature. Then, after these genes' loca-
tions in the original dataset were collected, the genes were
tested through multiple testing procedure in the training
set provided by Gordon et al [29]. Significant genes were
retained after the significant level was set as 0.05 to
exclude the non-significant genes.
The combination of the feature genes selected by PAM
method and from prior knowledge will be used to direct
following classification.
Classification via modified SVM
Support Vector Machines (SVM) developed by Cortes &
Vapnik [33] in 1995 for binary classification is currently a
hot topic in the machine learning theory and one of the
most powerful techniques for classification of microarray
data. SVM's basic idea for classification may be roughly
shown as follows, basically, we are looking for the opti-
mal separating hyperplane between the two classes by
maximizing the margin between the classes' closest points
(see Figure 1) – the points lying on the boundaries are
called support vectors H1 and H2, and the middle of the
margin H is the optimal separating hyperplane. Except for
linear decision making, SVM can also solve non-linear
problems by first mapping the data to some higher
dimensional feature space and constructing a separating
hyperplane in this space. Several kernel functions have
been introduced in order to deal with non-linear decision
surfaces, (1) linear kernel: K(x, y) = x￿y; (2) polynomial
kernel: K(x, y) = [(x￿y)+c]d, d = 1, 2, ...; (3) radial basis ker-
nel: K(x, y) = exp{-|x-y|2/σ2 }; (4) Sigmoid kernel: K(x, y)
= tanh [b(x￿y)+c], where b, c and σ are parameters.
Among these four types of kernel function, radial basis
kernel showed best performance according to the results
from similar studies [34,35]. The correct choice of kernel
parameters is crucial for obtaining good results, so an
extensive search must be conducted on the parameter
space before results can be trusted. Here we adopted radial
basis kernel function and 5-fold cross-validation in the
training set to search the best parameters for SVM-based
classification in the test set.
Evaluation of model performance
Classification accuracy and the standard deviations of our
proposed method (with prior knowledge) were compared
with the original one (no prior knowledge) in the training
set and test set. The framework of the above mentioned
procedures is shown in Figure 2.
Statistical analysis
All the statistical analyses were conducted using R statisti-
cal software version 2.80 (R foundation for Statistical
Computer, Vienna, Austria).
Results
Genes selected by PAM
The number of genes selected by PAM method varied
from 4 to 12 with an average 7.81, and the standard devi-
ation 2.21. The combination of genes selected by PAM is
shown in Table 1. Among them, CEACAM6, calretinin,
VAC-β and TACSTD1 appeared in the results all the time.
Gene selection via prior biological knowledge
After reviewed the full text of literature, twenty-three lung
adenocarcinoma-related genes were selected. Then, Table
2 lists the eight significant genes that passed the multiple
testing procedure in the training set provided by Gordon
et al. The details of these genes are shown in Table 2.
Evaluation of model performance
Our proposed method performed better after incorporat-
ing prior knowledge (Figure 3). Accuracy of the modified
method improved from 98.86% to 100% in training set
and from 98.51% to 99.06% in test set. The standard devi-
Classification via SVM (linear separable case) Figure 1
Classification via SVM (linear separable case).Journal of Experimental & Clinical Cancer Research 2009, 28:103 http://www.jeccr.com/content/28/1/103
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ation of the modified method decreased from 0.26% to 0
in training set and from 3.04% to 2.10% in test set.
Here, we considered another situation, if there was an
overlap between the two sources of genes, i.e. there existed
the multi-collinearity, was there any influence on the per-
formance of classification? Hence, taking into account the
effect of overlap seemed natural for the current study.
Expression quantity of VAC-β with a coefficient 1, 0.5 and
0.05 which meant complete, strong and minor correlation
was added to data set for comparison, respectively. The
accuracy in the above situation is 99.12%, 99.28%,
99.23% with the standard deviation 2.04%, 2.04%,
1.93%, respectively (Figure 3). McNemar's test was
adopted to compare the accuracy between 'no prior
knowledge' and the other 4 situations (with prior knowl-
edge, complete correlation with prior knowledge, strong
correlation with prior knowledge and minor correlation
with prior knowledge) in training set and test set, and all
the differences were statistically significant.
The accuracy in the training set was better than that in the
test set, and the standard deviations were lower in training
set than those in test set. Although Chi-square test indi-
cated that the differences between them were statistically
significant, the two sets were not comparable, and the dif-
ference may be caused by the large sample size. Training
set was used for training and fitting, while test set focused
on testing the ability to extrapolate.
Discussion
Microarrays are capable of determining the expression lev-
els of thousands of genes simultaneously and have greatly
facilitated the discovery of new biological knowledge
[36]. One feature of microarray data is that the number of
tumor samples collected tends to be much smaller than
the number of genes. The number for the former tends to
Framework of our proposed method Figure 2
Framework of our proposed method.
Table 1: Gene lists selected by Prediction Analysis for 
Microarrays
Gene name GenBank access No. Location at HG_U95Av2
ERBB3 M34309 1585_at
CD24 L33930 266_s_at
TACSTD2 J04152 291_s_at
UPK1B AB015234 32382_at
HIST1H2BD M60751 38576_at
TITF-1 U43203 33754_at
CLDN3 AB000714 33904_at
CEACAM6 M18728 36105_at
PTGIS D83402 36533_at
SFTPB J02761 37004_at
caltrtinin X56667 37157_at
VAC-β X16662 37954_at
claudin-7 AJ011497 38482_at
AGR2 AF038451 38827_at
TACSTD1 M93036 575_s_at
Table 2: Genes as prior biological knowledge
Gene name GenBank access No. Location at HG_U95Av2
CXCL1 J03561 408_at
IL-18 U90434 1165_at
AKAP12 X97335 37680_at
KLF6 U51869 37026_at
AXL M76125 38433_at
MMP-12 L23808 1482_g_at
PKP3 Z98265 41359_at
CYP2A13 U22028 1553_r_atJournal of Experimental & Clinical Cancer Research 2009, 28:103 http://www.jeccr.com/content/28/1/103
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be on the order of tens or hundreds, while microarray data
typically contain thousands of genes on each chip. In sta-
tistical terms, it is called 'large p, small n' problem, i.e. the
number of predictor variables is much larger than the
number of samples. Thus, microarrays present new chal-
lenge for statistical methods and improvement of existing
statistical methods is needed. Our research group's inter-
est is lung cancer, we found that one of the key issues in
lung cancer diagnosis was the discrimination of a primary
lung adenocarcinoma from a distant metastasis to the
lung, and so, it was important to identify which contrib-
ute most to the classification.
The present study used the combination of the genes
selected by PAM and the genes from published studies,
the result of this proposed idea was superior to that only
rely on the genes selected by PAM. Considered from the
methodological point, if the priori knowledge is not con-
trary to the truth, the incorporation of priori information
is able to improve the classification accuracy, at least can
not reduce the performance. From the point of accuracy
improvement, our result is of concordance with the results
of other previous studies [37,38]. It is interesting to com-
pare the list of 15 genes selected by PAM and 8 genes as
prior biological knowledge. In the current study, there was
no overlap between these two gene lists, but the situation
of overlap may be encountered in practice. Several genes
may share the same or similar functions, so the existing of
correlations among these genes from these two sources
should be considered. Our result indicated that after the
correlated gene had been added, no decrease of accuracy
was found, which meant that there was no need to pay
excess attention to the situation that overlapping existed
between the information from microarray data and prior
information.
One of the main limitations for the present study was how
to incorporate prior biological knowledge and where to
get it from. The prior biological knowledge in our study
was retrieved from the literature, while, with the develop-
ment of science and technology, huge knowledge will be
discovered and reported. The magnitude of prior knowl-
edge may have a certain impact on the results more or less.
What information can be used as the truth and which kind
of information should be excluded need to be further
explored, maybe some experience could be borrowed
from evidence-based medicine. On the other hand, the
minimum number of predictor genes is not known, which
may serve as a potential limitation of the study, and the
discrimination function can vary (for the same genes)
based on the location and protocol used for sample prep-
aration [39]. The complexity of discriminant analysis and
the multiple choices among the available discriminant
methods are quite difficult tasks, which may influence the
adoption by the clinicians in the future. Although highly
accurate, microarray data's widespread clinical relevance
and applicability are still unresolved.
Conclusion
In summary, a simple and general framework to incorpo-
rate prior knowledge into discriminant analysis was pro-
posed. Our method seems to be useful for the
Accuracy comparisons, no prior knowledge vs. with prior knowledge Figure 3
Accuracy comparisons, no prior knowledge vs. with prior knowledge. Note: * Accuracy is significantly higher when 
compared to no prior knowledge at the 0.05 level (2-tailed). ** Accuracy is significantly higher when compared to no prior 
knowledge at the 0.01 level (2-tailed).
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improvement of classification accuracy. This idea may
have good future not only in practice but also in method-
ology.
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